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Purpose: Serum creatinine functions as a poor surrogate marker of renal allograft dysfunction
and long-term graft survival. By measuring multiple proteins simultaneously in the serum of
transplant patients, we can identify unique protein signatures of graft dysfunction.
Experimental design: We utilized training and validation cohorts composed of healthy and
volunteer subjects, stable renal transplant patients, and renal transplant patients experienc-
ing acute allograft rejection. Utilizing our antibody microarray, we measured 108 proteins
simultaneously in these groups.
Results: Using Mann–Whitney tests with Bonferroni correction, we identified ten serum
proteins from 19 renal transplant patients with stable renal function, which are differentially
expressed, compared to healthy control subjects. In addition, we identified 17 proteins that dif-
ferentiate rejecting renal transplant recipients from stable renal transplant. Validation cohorts
substantiated these findings.
Conclusion and clinical relevance: Our preliminary results support that a specific pattern of
protein expression or “protein signature” may be able to differentiate between stable transplant
patients from those with rejection. Future studies will focus on other etiologies of renal allograft
dysfunction and the effect of treatment on protein expression and long-term outcome.
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1 Introduction
Although one year kidney graft survival is greater than 90%
due to improved immunosuppression, long-term kidney al-
lograft outcome has not changed dramatically over the last
decade [1]. Several factors that influence long-term kidney
transplant function include immunologic injury from ei-
ther acute cellular or antibody-mediated rejection, calcineurin
inhibitor (CNI) nephrotoxicity, BK virus (BKV) associated
nephropathy, and metabolic derangements, all of which re-
sult in chronic allograft injury and subsequent loss of the
transplanted graft [2]. The long-term success of kidney trans-
plantation traditionally relies on serum creatinine (Scr) levels
as the surrogate marker to follow renal allograft function
and graft survival [3]. The early and prompt detection of re-
nal allograft dysfunction and understanding of its associated
mechanisms may improve the long-term outcome. Renal al-
lograft biopsy, though imperfect and invasive, is the current
gold standard to achieve such objective.
For years, investigators have been searching for alter-
native, noninvasive, and easy to use methods to detect
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renal allograft dysfunction. Initial studies included blood and
urine flow cytometry [4,5], and over the years, enzyme-linked
immunoassays [6–9], NMR [10], mass spectroscopy [11, 12],
PCR [13–17], and gene microarrays [18,19] of both urine and
blood have been used in an attempt to diagnose the etiology
of renal allograft dysfunction [20]. Although each of these
methods has strengths and weaknesses, these techniques
have led to identification of specific genes, transcripts,
and proteins important in renal transplant injury. Yet,
widespread clinical application of each of those methods has
not been accomplished.
We have developed an antibody microarray that can mea-
sure multiple proteins, including those involved in inflam-
mation, rejection, and renal tubular injury, simultaneously in
biological samples such as serum from transplant patients.
Our array can measure many proteins of interest including
those involved in inflammation, rejection, and renal tubular
injury and has been previously been used in our lab to iden-
tify biomarkers in vasculitis [21]. Our current antibody array
measures 108 proteins simultaneously and is limited only by
the number of antibody pairs commercially available for hu-
man protein detection. In this study, we have identified a set
of proteins that have differential expression among healthy
controls, stable renal transplant patients, and renal transplant
patients with rejection.
2 Materials and methods
2.1 Study population
We included a training cohort and a validation cohort. Each
cohort is composed of three groups: healthy and volunteer
subjects, stable renal transplant patients, and renal transplant
patients experiencing acute rejection of renal allograft.
Healthy and volunteer subjects came from two sources:
those enrolled as healthy control in the Pfizer CRC clinic
(Protocol #394-0) and those employees in our institution. All
subjects met the following criteria: (i) normal renal func-
tion, as judged by normal Scr levels; (ii) no over the counter
painmedications for 1wk, (iii) no steroidal anti-inflammatory
drugs for at least 6 months, and (iv) no overt signs of illness.
In addition, other serum chemistries and cell blood counts
were normal.
Stable renal transplant patients were defined as having
normal and stable Scr levels (Scr< 1.5 mg/dL) and without a
clinical indication for a renal allograft biopsy (a Scr increase
≥ 25% over the baseline values). The “to be discarded serum
samples” on their routine clinic visit daywere collected aswell
as other pertinent laboratory values and clinical information.
Renal transplant patients experiencing acute rejection un-
derwent renal allograft biopsy to confirm the clinical suspi-
cion of rejection. The Banff 07 classificationwas used to grade
the rejection. The discarded serum samples on the day of re-
nal allograft biopsy were collected. The clinical information
and other pertinent laboratory values were collected as well
on the day of biopsy.
Samples collection for training cohort occurred from Oc-
tober 2007 to February 2010 and for validation cohort from
March 2010 through February 2011.
This study was approved by the institutional review board
at the University of Michigan (Protocol #IRB 2000-0005)
2.2 Immunosuppression
Triple drug regimen consisting of a CNI, mycophenolic acid,
and prednisone was used for all but five renal transplant
patients. Four patients were on experimental immunosup-
pression at the time of serum collection and one patient was
on no immunosuppression (self-discontinuation due to lack
of insurance; Scr 0.9; no proteinuria).
2.3 Antibody array
Antibodymicroarrays were generated as previously described
[22] using commercially available antibody pairs and stan-
dard proteins (R&D Systems, Minneapolis, MN). The 108
antibodies used for this analysis were run as three sepa-
rate MicroArrays. This method was done based on problems
with nonspecific binding, which frequently occur when poly-
clonal antibodies are utilized in this technology. Antibody ar-
rays were spotted using a PiezorrayTM (PerkinElmer, Boston,
MA) targeted to 16 specific subarrays, designed to work with
the ProPlateTM system (Grace Bio-labs/Molecular Probes, Eu-
gene, OR). Capture antibodies were diluted in spotting buffer
and spotted in five replicate spots onto EpoxyES microarray
slides (Erie Scientific, Portsmouth, NH; 39). As a control for
nonspecific binding, isotype control and nonspecific IgG an-
tibodies (rabbit, mouse, and goat) were spotted in each array.
For optimization, array components were tested over a range
of concentrations; capture antibodies (25–500 g/mL), stan-
dard curves of commercial proteins (1.22–5000 pg/mL), and
secondary antibody (diluted 1:200–1:1000). Antibodymicroar-
rays were hybridized, scanned, and quantified as outlined
below. Standard curves for the arrays were considered ac-
ceptable when they achieved an r2 of 0.95 or greater for quan-
tification. An optimized antibody pair was defined as provid-
ing a median fluorescent intensity (MFI) that responded in a
dose-dependent manner and did not saturate the MFI. Once
an optimal array was achieved, percent recovery and cross-
reactivity of standards (1000 pg/mL) spiked into normal hu-
man serum was determined and any antibody that showed
nonspecific cross-reactivity was excluded from the array.
In addition, we performed conventional ELISAs on sev-
eral of the current patient samples and found a 0.94 cor-
relation with the MicroArray values. As the MicroArray is
an ELISA-based system, we utilized the same antibody pairs
(R&D DuoSets) for the conventional ELISA and produced
similar standard curves and values as in the MicroArray.
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2.4 Hybridization
Standards were diluted into Tris-buffered saline pH 7.4
(Rockland, Gilbertsville, PA) with 0.1% Tween-20 (TBS-t)
and 5% BSA (Sigma, St. Louis, MO) and serum samples (80
L of serum) were diluted fourfold in TBS-t. The EpoxyES-
coated slides were placed in the ProPlateTM system and
washed five times with TBS-t and blocked for 30 min at room
temperature (RT) with 0.5% dry milk, 0.5% BSA (Sigma) in
TBS-t on a rotating platform at RT. Chips were washed thrice
with TBS-t, standards and diluted serum samples added to
the chip (100 L per well). They were covered and placed
on a rotating platform at 4C overnight. Arrays were washed
five times with TBS-t, secondary antibodies diluted in block-
ing solution were added and incubated for 2 h on a rotating
platform at RT. Arrays were washed five times with TBS-t,
100 L of Alexa Fluor 647-strepavidin (Molecular Probes) di-
luted 1:2500 in blocking solutionwas added and incubated for
30 min at RT on a rotating platform in the dark. Arrays were
washed three times in TBS-t, removed from the ProPlateTM
system, dipped in TBS, then into double distilled H2O, and
dried using compressed air. Slides were stored in the dark at
RT until scanned.
2.5 Quantification
Slides were scanned on an Axon 4000B using GenePix 6.0
(Axon Instruments/Molecular Devices, Sunnyvale, CA). A
single laser was used and laser intensity was adjusted so that
the highest standards were not saturated and the same inten-
sity was used for all slides processed using the same exper-
iment. MFI data minus the background was used to gener-
ate the standard curve. Unknowns were calculated using the
curve fitting function and quantifiable analytes were plotted
based on concentration. Unknowns that were not within the
standard linear range or had a high nonspecific background
in the isotype antibody controls were excluded from analysis.
2.6 Statistics
Of the original 108 biomarkers (seeAppendix), 24 biomarkers
were excluded from the healthy subjects versus stable renal
transplant analysis and 31 biomarkers were excluded from
the stable versus rejecting renal transplant analysis because
either the standard deviation was zero or the results did not
fall on the standard curve. For the remaining biomarkers, the
nonparametric Mann–Whitney rank-based test was used to
assess the difference between themedians for each biomarker
in each cohort since the majority of the biomarkers did not
follow a normal distribution and theMann–Whitney test does
not require normality and is robust to outliers. Interestingly,
the two-sample t-test gave almost the same results for thema-
jority of the proteins analyzed even though the t-test is suit-
able for samples with a normal distribution (data not shown).
In addition to the univariate tests, (i) a least angle regres-
sion analysis (LARS) was used to select a set of simultaneous
markers that best predict groupmembership in amultivariate
logistic regression model [23] and (ii) a multivariate analysis
was performed that was adjusted for the recipient’s race, age,
and gender; Scr, donor source, and time post-transplantation.
The results were identical to the original, unadjusted analy-
sis (data not shown). Unlike traditional regression methods,
LARS can be used when the number of predictors is larger
than the sample size without over fitting the model [23, 24].
The key feature of the LARS approach is that regression co-
efficients are penalized toward zero with the least predictive
markers being excluded by estimating their coefficients ex-
actly zero. The advantage of the LARSmethod is to adjust the
effects of other biomarkers so that a relatively weak biomarker
can stand out to a greater extent. This procedure yields a pre-
diction model that is both parsimonious and interpretable.
Interactions between selected markers were also tested. We
ran the LASSO with all biomarkers included initially in order
to select important markers in a multivariate setting. Those
markers selected by the LASSO were then examined for their
interaction terms because it is difficult to interpret an inter-
action term when one of the involved factors is not important
in its main effect. Two-way interaction terms were created be-
tween each pair of these markers and included in the LASSO
along with the main effects, which were forced into the final
model. No interaction term was selected by the LASSO for
inclusion in the final model.
To examine the prediction capability, receiver-operator
curves (ROCs) were generated on the biomarkers that were
found to be significant by the Mann–Whitney test. t-Tests,
Mann–Whitney tests, and ROC were repeated on the valida-
tion cohort.
To assess whether actual transplant patients could be pre-
dicted by the model, that is the set of ten biomarkers, a linear
discriminant analysis (LDA) was used for the ten healthy con-
trol subjects and the 19 stable renal transplant recipients. The
same model was then used to predict group membership in
the validation cohort.
The analysis was completed with and without one out-
lier (sample #22) and the results compared. To account for
multiple testing using a Bonferroni correction, significance
of the Mann–Whitney test was achieved at a level of  =
5.952 × 10−4 when comparing healthy subjects to stable re-
nal transplant patients and at a level of 6.494 × 10−4 when
comparing stable to rejecting renal transplant patients. The
Mann–Whitney test, t-tests, LDA, and ROC were performed
in SAS 9.1 (SAS Institute, Cary, NC) and the LARS procedure
in the GLM path package in R 2.9.1 [24].
3 Results
Demographic and pertinent clinical information for the train-
ing and validation cohorts are shown in Tables 1 and 2. In
the training cohort (Table 1), healthy subjects and rejecting
transplant patients were younger and predominantly male as
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Table 1. Demographic variables of the training cohorts
Healthy controls (n = 10) Stable patients (n = 19) Rejecting patients (n = 15)
Mean age (years) 41.70 ± 15.45 59.9 ± 13.0 45 ± 11.1
R. race (Caucasian) N/A 19 (100%) 12 (80%)
R. gender (n,% male) 6 (60%) 5 (26%) 9 (60%)
ESRD (diabetes) N/A 6 4
Months post-transplant N/A 50.4 ± 31.0 13.1 ± 18.9
Transplant type (n,% living donor [LD]) N/A 11 (58%) 8 (53%)
Donor age (years)a) N/A 37.2 ± 13.4 34.9 ± 16.9
Donor gender (n,% male)a) N/A 6 (33%) 8 (61%)
CMV status (D+/R−) N/A 2 4
Mean scr (mg/dL) 0.95 ± 0.25 1.1 ± 0.23 2.6 ± 0.86
CNI (CSA/TAC)b) N/A 10/8 12/2
a) Donor age and gender are missing for some patients.
b) One patient was not on any CNI and a few patients were on study drug.
ESRD, end-stage renal disease; R, recipient; D, donor; CMV, cytomegalovirus; CSA, cyclosporine; TAC, tacrolimus.
compared to stable renal transplant recipients. Patients with
rejection had shorter post-transplant follow-up (13.1 ± 18.9
vs. 50.4 ± 31.0 months) and had higher Scr levels (2.6 ± 0.9
vs. 1.1± 0.2mg/dL) as compared to stable renal transplant pa-
tients. Similar patterns were observed among subjects within
the validation cohort (Table 2). While cyclosporine-based im-
munosuppression was more often used among transplant
patientswithin the training cohort, the patientswithin the val-
idation cohort received more frequently Tac-based immuno-
suppression.
Of the 108 proteins that were assayed (Appendix for com-
plete list of proteins on array), ten protein biomarkers were
identified that were significantly different between healthy
subjects and stable renal transplant patients (Table 3). Al-
though the renal biomarkers, cystatin C and kidney injury
molecule-1 (KIM-1), differ significantly between healthy sub-
jects and stable renal transplant patients aswould be expected,
levels of cystatin C were significantly increased (188 005 vs.
84 023 pg/mL; p = 3.63 × 10−5) and levels of KIM-1 were
significantly decreased (872 vs. 3620 pg/mL; p = 6.70 ×
10−6) as compared to the healthy controls. In addition, mono-
cyte chemotactic protein-1 and -3 (MCP-1; MCP-3) and tissue
inhibitor matrix metalloproteinase-4 (TIMP-4) were signifi-
cantly higher in stable renal transplant recipients. In con-
trast, five markers were significantly lower in stable renal
transplant patients as compared to healthy subjects: epider-
mal growth factor (EGF), granulocyte-macrophage colony-
stimulating factor (GM-CSF), interleukin-5 (IL-5), IL-1 recep-
tor 1, and macrophage migration inhibitory factor (MIF).
Table 4 shows the protein signature differentiating stable
renal transplant recipients from those renal transplant pa-
tients with rejection. Seventeen proteins were found to be
significantly different between these two groups. Compared
to stable transplant recipients, patients with rejection had
lower amounts of E-cadherin, EGF, erythropoietin receptor
(EPO-R), growth regulated oncogene-alpha (GRO), inter-
leukin 6 (IL-6), MCP-1, macrophage inflammatory protein
3-alpha (MIP-3), transforming growth factor (TGF)1, and
TGF2 and higher amounts of GM-CSF, interleukin 1 re-
ceptor 1 (IL-1R1), interleukin 12 p70 (IL-12p70), KIM-1, MIF,






IIb) (n = 14)a)
Rejecting
patients (n = 13)
Mean age (years) 30.26 ± 8.45 49.9 ± 12.6 53.5 ± 15.96 38.77 ± 14.86
R. race (Caucasian) 7 (47%) 13 (86%) 12 (86%) 6 (46%)
R. gender (n,% male) 10 (67%) 8 (53%) 6 (43%) 4 (31%)
ESRD (diabetes) N/A 6 5 4
Months post-transplant N/A 56.1 + 50.9 54.4 ± 45.5 14.0 ± 17.24
Transplant type (n,% LD) N/A 5 (33%) 5 (36%) 6 (46%)
Donor age (years)c) N/A 30.1 ± 14.1 33.7 ± 17.1 39.7 ± 13.0
Donor gender (n,% male)c) N/A 5 (42%) 6 (43%) 6 (46%)
CMV status (D+/R−) N/A 4 5 3
Mean scr (mg/dL) 1.0 ± 0.15 1.05 ± 0.13 2.29 ± 0.85
CNI (CSA/TAC)a) N/A 6/8 6/7 3/10
a) One patient was not on any CNI and a few patients were on study drug.
b) A new stable transplant validation cohort was used in the rejection analysis.
c) Donor age and gender are missing for some patients.
ESRD, end-stage renal disease; R, recipient; D, donor; CMV, cytomegalovirus; CSA, cyclosporine; TAC, tacrolimus.
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Table 3. Protein signature of stable renal transplant recipients versus healthy controls
Marker Healthy controls (N = 10) Stable transplants (N = 19) p-Value
Cystatin-C 84 023 (38 433, 123 381) 188 005 (69 878, 400 000) 3.630 × 10−5
EGF 1756 (1078, 2259) 419 (151, 2840) 2.690 × 10−5
GM-CSF 2275 (967, 4000) 412 (149, 4000) 4.680 × 10−5
IL-1 R1 15 970 (7284, 20 419) 2667 (2405, 30 299) 1.930 × 10−5
IL-5 409 (294, 751) 82 (22, 648) 4.643 × 10−4
KIM-1 3620 (1378, 10 872) 872 (450, 4102) 6.700 × 10−6
MCP-1 418 (275, 644) 841 (471, 1499) 3.000 × 10−6
MCP-3a) 358 (249, 673) 1943 (222, 2000) 1.044 × 10−4
MIF 6163 (2665, 7498) 2541 (1150, 6797) 4.880 × 10−5
TIMP-4a) 6667 (5437, 7843) 8000 (6521, 8000) 1.300 × 10−6
a) p-Value is conservative due to truncation of data in the stable transplants.
Median values are in picograms/milliliter with the range in parentheses.
p-Value ≤ 5.952 × 10 −4 was consider statistically significant.
osteopontin, tumor necrosis factor receptor II (TNF-RII), and
vascular endothelial growth factor receptor 2 (VEGF-R2). Fur-
thermore, six of these 17 proteins, namely EGF, GM-CSF,
IL-1R1, KIM-1, MCP-1, and MIF, were also differentially ex-
pressed between healthy controls and stable renal transplant
patients. In addition, a multivariate analysis was performed
that was adjusted for the recipient’s race, age, and gender;
Scr, donor source, and time post-transplantation. The results
were identical to the original, unadjusted analysis (data not
shown).
The protein signatures for those renal transplant recipi-
entswith biopsy-proven chronic allograft nephropathy (CAN),
acute tubular necrosis (ATN), CNI nephrotoxicity, and BKV
nephropathy are shown in Table 5. Significant differences in
the levels of several biomarkers can be seen when each con-
dition was compared to stable renal transplant recipients. For
example, in those patients with CAN, significant differences
were observed in connective tissue growth factor, E-cadherin,
and KIM-1 as compared to stable renal transplant recipients.
Since tubular injury and dropout are common features of
CAN, it is not unexpected to see elevations in such biomarkers
as KIM-1. In contrast, HSP27 and nephrin were significantly
decreased in patients with BKV and a significant difference in
HSP27 expression was only seen in those patients with BKV
nephropathy (HSP27 expressions was numerically higher in
all other groups as compared to stable patients). Interestingly,
HSP27 has been shown to be involved in viral infection, repli-
cation, and downstream signaling events in virus-infected
cells [25, 26]. As for renal transplant patients with ATN
or CNI nephrotoxicity, other biomarkers were significantly
Table 4. Protein signature of stable patients and rejecting patients
Biomarkers Stable transplants (n = 19) Rejecting transplants (n = 15) Mann–Whitney p-value
TGF-2 2320 (2044, 9628) 980 (85, 1234) 5.388 × 10−10
E-cadherin 8488 (1892, 48 000) 170 (3, 360) 1.078 × 10−9
GRO 5281 (2344, 8000) 358 (124, 976) 1.078 × 10−9
TGF-1 256 (157, 1111) 89 (45, 121) 1.078 × 10−9
IL-6 575 (183, 4000) 73 (4, 231) 4.310 × 10−9
IL-1 R1a) 2667 (2405, 30 299) 32 000 (8530, 32 000)b) 2.802 × 10−8
EGFa) 418 (151, 2840) 114 (8, 208) 3.233 × 10−8
MIP-3 375 (164, 1167) 82 (18, 304) 4.849 × 10−8
TNF-RII 2138 (1146, 4177) 5994 (565, 6400) 7.423 × 10−6
KIM-1a) 872 (450, 4102) 2364 (999, 5706) 9.663 × 10−6
Osteopontin 24 145 (11 911, 51 053) 66 802 (27 754, 89 010) 1.211 × 10−5
VEGF-R2 12 (12, 8000) 8000 (18, 8000)b) 1.491 × 10−5
Epo-R 57 387 (10 926, 80 000) 22 201 (13 635, 47 932) 8.929 × 10−5
MIFa) 2541 (1150, 6797) 3874 (2800, 6214) 1.096 × 10−4
IL-12p70 2900 (88, 8000) 8000 (6900, 8000)b) 1.168 × 10−4
MCP-1a) 841 (471, 1499) 122 (27, 4000) 1.300 × 10−4
GM-CSFa) 412 (149, 4000) 1100 (210, 2305) 3.494 × 10−4
a) Statistically different between healthy controls and stable patients.
b) p-Value is conservative due to truncation of the data in rejecting patients.
Bold values are protein biomarkers common to both stable and rejecting patients.
Median values are in picograms/milliliter with the range in parentheses.
p-Value ≤ 6.494 × 10 −4 was consider statistically significant.
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Clinical Relevance
While the 1 year kidney graft survival is greater than
90% due to improved immunosuppression, long-
term outcome has not changed dramatically over
the last decade. Factors that influence long-term kid-
ney transplant function include immunologic injury
from acute cellular or antibody-mediated rejection,
CNI nephrotoxicity, and BKV-associated nephropa-
thy, all of which result in chronic allograft injury and
subsequent loss of the transplanted graft. The long-
term success of kidney transplantation traditionally
depends on Scr levels as the surrogate marker of re-
nal allograft function. Although invasive, renal allo-
graft biopsy is currently the accepted approach used
to detect renal allograft dysfunction. Using the pro-
tein array, early and prompt detection of renal al-
lograft dysfunction may help improve long-term out-
comes. Our preliminary results support that a specific
pattern of protein expression or “protein signature”
may be able to differentiate between stable trans-
plant patients from those with rejection.
different when compared to stable renal transplant recipients
(Table 5). Across all conditions, transforming growth factor
beta 1 (TGF-1) and vascular endothelial growth factor were
significantly lower than in stable renal transplant patients
(data not shown).
Tables 6 and 7 display the LDAmodels for the biomarkers
of both the training and validation cohorts. Table 6 displays
the LDA model to determine the accuracy of these ten
biomarkers to predict whether a protein signature defined
a healthy subject or a stable renal transplant patient. For
the training cohort, no control subjects and three transplant
patients were misclassified by the LDA model. For the
validation cohort, no healthy control subjects and no stable
renal transplant patients weremisclassified as having a stable
transplant patient and healthy subject profile, respectively.
Nonetheless, the p-values for the table and whether the
AUC = 0.50 were statistically significant with an AUC
of 1.0 for both the training and the validation cohorts,
demonstrating that these ten biomarkers could predict
accurately the protein signature of a healthy subject versus
a renal transplant recipient. Table 7 displays the LDA model
to determine the accuracy of these 17 protein biomarkers to
predict whether a protein signature defined a stable renal
transplant patient or a rejecting renal transplant patient.
For both the training and validation cohorts, no stable renal
transplant patients and no transplant patients with rejection
were misclassified by the LDA model yielding an AUC of 1.0
for both the training and validation cohorts.
The ROCs analysis for the biomarkers identified in the
training cohort by the Mann–Whitney test demonstrated the
AUC for the ten biomarkers using the validation cohort is 1.0,
suggesting that these ten biomarkers can differentiate healthy
subjects from stable renal transplant patients (Fig. 1A). Sim-
ilarly, the AUC for the 17 biomarkers differentiating stable
from rejecting renal transplant patients in the validation set
is 1.0 (data not shown). In addition, the ROC of the individual
biomarker MCP-1 (Fig. 1B), using the validation cohort, has
an AUC that approaches 1.0 (0.960). The ROCs for the other
biomarkers were similar to the ROCs generated for MCP-1
andMIF (data not shown). The training set ROC (AUC= 1.0)
was similar to the validation set ROC (data not shown).
4 Discussion
Formany years, studies have attempted to link a specific gene,
transcript, or protein or a pattern of genes or transcripts with
renal allograft dysfunction [4–19]. To date, no specific gene,
Table 5. Differences in protein expression of the seven protein biomarkers common to kidney transplant patients diagnosed with CAN,
ATN, CNI, or BKV injury
Biomarkers Stable transplantsa)
(n = 12)
CANa) (n = 12) ATNa) (n = 13) CNIa) (n = 6) BKVa) (n = 12)
Clusterin (ng/mL) 202 778 ± 48 446 205 208 ± 22 014 102 486 ± 12 449b) 115 138 ± 17 805b) 136 762 ± 35 181
CTGF (pg/mL) 968 ± 681 315 ± 62b) 702 ± 511 327 ± 476 969 ± 898
E-cadherin (pg/mL) 4914 ± 2971 825 ± 192b) 104 ± 39b) 1412 ± 1692 5617 ± 2633
Fibronectin (ng/mL) 509 838 ± 86 752 480 208 ± 33 037 184 879 ± 37 565b) 252 520 ± 47 431b) 347 560 ± 184 975
HSP27 (pg/mL) 3703 ± 2414 6174 ± 1409 4124 ± 1800 15 263 ± 8916 268 ± 124b)
KIM-1 (pg/mL) 744 ± 565 2994 ± 1459b) 453 ± 346 640 ± 847 1172 ± 2290
Nephrin (ng/mL) 67 ± 28 146 ± 104 4.2 ± 11b) 2.6 ± 1.1b) 8.3 ± 12.2b)
a) Mean values are either in picograms/milliliter or nanograms/milliliter along with the SD.
b) Proteins significantly different from stable patients: p-value ≤ 0.001136.
Each cohort in this table was compared to stable renal transplant recipients.
CTGF, connective tissue growth factor.
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Table 6. Linear discriminant analysis model for the ten biomarkers of the training and validation cohorts
Cross-validation ControlActual Txp.Actual
Using markers significant in Mann–Whitney tests for the training cohort
Apparent error rate = 3/30 or 10%
ControlPredicted 10 3
TransplantPredicted 0 16 AUC = 1.0 (p = 1.51 × 10−6)
Making predictions using the validation cohort
Apparent error rate = 0
ControlsPredicted 15 0
TransplantPredicted 0 15 AUC = 1.0 (p = 1.29 × 10−8)
Linear discriminant analysis of ten healthy subjects versus 19 stable renal transplant patients in the training cohort to assess whether
transplant patients could be predicted by the model. New healthy subjects and stable transplant patients were used for the validation
analysis. Txp, stable renal transplant patients; AUC, area under concentration curve.
protein, or pattern has been identified that is specific for renal
allograft dysfunction. The problemswith these previous stud-
ies are twofold. First, a priori assumptions have been made
to link a specific transcript or protein with a particular condi-
tion. Second, upregulated genes and transcripts may not be
translated into proteins so that differences observed among
genes or transcripts may not correlate with renal pathology.
Most likely, a pattern of proteins and not a single protein
will define the complex, pathological process leading to renal
allograft dysfunction. Thus, identification of a protein signa-
ture that is specific for the various etiologies of renal allograft
dysfunction is paramount.
Our study demonstrates that protein array can be used to
identify a specific protein signature for stable renal allograft
function from those with impaired function from rejection.
To avoid a priori assumptions, the 108 proteins on the array
represent a large variety of cellular proteins including, but
not limited to, cytokine/chemokines, their receptors and an-
tagonists, cell adhesion molecules, growth and angiogenesis
factors, proteases and their inhibitors, matrix metallopro-
teinases (MMPs) and their inhibitors, HSPs, complement
factors, and anticoagulant factors. By assaying a wide variety
of proteins, a priori assumptions are limited only by the
number of commercially available antibody pairs for plating.
Our preliminary results support that a specific pattern
of protein expression or “protein signature” may be able to
differentiate between stable transplant patients from those
with rejection. First, we identified a protein signature that
distinguishes healthy subjects from renal transplant patients
with good allograft function and no previous history of re-
jection. Ten proteins reliably differentiate stable renal trans-
plant recipients from healthy subjects in both the training
and validation cohorts. Of these ten proteins, six proteins
have lower expression and four proteins (cystatin C, MCP-1,
MCP-3, TIMP-4) have higher expression in the stable renal
transplant cohort as compared to healthy controls. Second, we
identified a protein signature that distinguishes stable renal
transplant patients from those with rejection. Seventeen pro-
teins differentiate rejecting renal transplant recipients from
stable renal transplant patients in both training and validation
cohorts. Of these 17 proteins, nine have lower levels expres-
sion and eight have higher levels of expression in the reject-
ing cohort as compared to the stable renal transplant cohort.
Interestingly, six proteins are common to both the protein
signature of the stable and the rejecting patients but vary
significantly in their levels of expression. For example, EGF
expression is highest in the healthy controls and decreases
in expression in the stable and rejecting renal transplant pa-
tients. In contrast, the other five proteins (GMCSF, IL-1 R1,
KIM-1, MCP-1, MIF) are depressed in stable renal transplant
patients and are at higher levels in the healthy controls and
in the rejecting renal transplant patients suggesting similar
Table 7. Linear discriminant analysis model for the 17 biomarkers of the training and validation cohorts
Cross-validation in training set StableActual RejectingActual
Using markers significant in Mann–Whitney tests for the training cohort
Apparent error rate = 0
StablePredicted 19 0
RejectingPredicted 0 15 AUC = 1 (p = 1.30 × 10−7)
Making predictions using the validation cohort
Apparent error rate = 0
StablePredicted 14 0
RejectingPredicted 0 13 AUC = 1 (p = 2.72 × 10−6)
Linear discriminant analysis of 19 stable renal transplant patients versus 15 renal transplant patients with rejection in the training cohort
to assess whether rejecting transplant patients could be predicted by the model. New stable and rejecting transplant patients were used
for the validation analysis; AUC, area under concentration curve.
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Figure 1. ROCs for the protein biomarkers for the validation co-
hort and one representative proteins. (A) ROC using all ten signif-
icant biomarkers that differentiate stable renal transplant patients
from healthy control subjects. (B) ROC for MCP-1 in the validation
cohort.
immunoreactivity between the healthy controls and rejecting
renal transplant patients. Given the various levels of protein
expression among the cohorts, our protein array reflects the
spectrum and complexity of the disease process.
In a previous study, KIM-1, a protein marker present
in urine of patients with renal disease, was undetectable
in healthy controls [27]. In our study, KIM-1 was detected in
healthy controls but the detection limit of our array is 1000
times more sensitive than the ELISA used in their study and
the biological fluid of choice in our study was serum, not
urine, due to the stability of proteins at a neutral pH. In
a contrasting study using LC and mass spectroscopy, Ling
and colleagues identified a urine peptidome and correlated it
with renal transplant biopsy transcriptome for rejection [28].
They identified a six gene biomarker panel for acute rejection
(COL1A2, COL3A1, UMOD, MMP-7, SERPING1, TIMP-1).
Interestingly, our protein array identified a TIMP-4 that dif-
ferentiated healthy subjects from stable renal transplant pa-
tients and that was also present in patients with rejection but
only trended toward statistical significance. As these authors
found, we believe that collagen biomarkers are also important
determinants of renal allograft dysfunction and are currently
being incorporated into our protein array.
Our protein array has several advantages. First, it allows
for the measurement of over a 100 proteins simultaneously
and identifies a pattern of protein biomarkers specific for
renal allograft dysfunction. Second, since the protein array
is noninvasive, it could be used to follow patients longitu-
dinally and to detect subclinical renal allograft dysfunction
before it would be detected by conventional methods (i.e.
Scr). By detecting renal allograft dysfunction earlier, long-
term graft outcomes could be positively impacted. Third,
since the array allows for detection of protein differences
in serum, an acidic pH as in urine is not a concern. Protein
array chips can also be tailored for specific pathological con-
ditions so that 100 proteins do not need to be assayed every
time. Lastly, by identifying specific proteins involved in the
rejection process, new targets for therapeutic agents could be
developed.
There are several limitations to our study. Since the array
can only be constructed from antibody pairs that are com-
mercially available, this limitation restricts the number of
proteins that can be assayed in the serum. As more antibody
pairs become available, the numbers of proteins that can be
assayed on the array will increase to where 150 proteins per
chip and several chips at a given time can be assayed simul-
taneously. Another major limitation is the lack of protocol
renal transplant biopsies in the stable renal transplant cohort
to validate their Scr levels. Since renal transplant protocol
biopsies have now become standard at our institution, future
studies will no longer have this limitation. Due to the nature
of this work being a pilot study, other protein patterns of renal
allograft dysfunction such as BK nephropathy have yet to be
elucidated, even though preliminary data from our protein
array can differentiate between ATN and CNI toxicity. The
sample size in our study limits the ability to perform inter-
action models among the proteins of interest and the ROCs.
For example, the AUC from the ROC for the validation cohort
is 1.0, which most likely reflects the small sample size. In the
Ling et al. paper [28], the AUCs approached 1.0 as well, most
likely due to the small sample size in their study. Although
our array can measure proteins in the urine (unpublished
data), we chose to use serum samples due to the neutral pH
and stability of proteins in serum to protect protein integrity.
The majority patients in our cohorts were Caucasian (only
∼20% of patients in our institution are African American).
In contrast, the validation cohort did include Asians and one
African American and yet the results were similar to the
training transplant cohort. Lastly, a control cohort of patients
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with other inflammatory conditions such as lupus nephritis
or rheumatoid arthritis would have reinforced of our results.
A statistical concern is that biomarkers with nonsignifi-
cant p-values may strongly discriminate between two cohorts
when brought together in a protein signature. In the current
literature, the univariate analysis approach based on p-values
is popular (perhaps the first choice of screening analysis) be-
cause of its computational convenience. However, it has two
major weaknesses: (i) biomarkers that are not associated with
the disease but strongly associated with a significant disease
predictor can be selected as important biomarkers [27]; and
(ii) a biomarker that is marginally uncorrelated but jointly
associated with the disease outcome cannot be identified by
such a simple univariate analysis method based on p-values
[28]. These shortcomings can be overcome by joint screening
methods such as the LASSO used in our manuscript.
In summary, using protein array methodology, we were
able to differentiate stable renal transplant patients from
those patients with rejection. In addition, our results support
that a group of proteins are involved in the disease process and
the pattern of protein expression or a “protein signature” is
necessary to differentiate between various disease processes.
Given the promising results of our current study, future di-
rections for the protein array will include determination of
the protein signature for other etiologies of renal allograft
dysfunction such as BK nephropathy, chronic allograft in-
jury, antibody-mediated rejection, and CNI nephrotoxicity. In
addition, patient samples will be collected prospectively and
longitudinally to determine the effect of treatment on the
protein signature and to correlate it with patient outcomes.
No agency supported this research. The content is solely the
responsibility of the authors.
The authors have declared no conflict of interest.
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Appendix
Table A1 Human antibody array performance
Proteins Range (pg/mL) Curve fit r2 Proteins Range (pg/mL) Curve fit r2
ACE 31–8000 0.992 IL-12p70 750–2000 0.991
Activin A 333–8000 0.989 IL-13 6–6000 0.965
ADAM8 354–4000 0.994 IL-15 4–1000 0.996
Adiponectin 1000–4000 0.981 IL-18 BP 1875–6000 0.997
ALCAM 7.81–8000 0.976 IP-10 125–2000 0.991
BCAM 208–4000 0.992 Leptin 8–2000 0.961
BLC/BCA-1 83–1000 0.982 L-selectin 5–5000 0.982
-NGF 105–2000 0.999 MCP-1 42–1000 0.976
Cathepsin S 58–1000 0.984 MCP-2 300–4000 0.997
Complement D 8–2000 0.987 MCP-3 23–500 0.994
CTGF 4–1000 0.996 MCP-4 2–500 0.992
Dectin-1 2500–10 000 0.991 MIF 250–2000 0.993
E-cadherin 12–12 000 0.999 MIP-1 26–1000 0.983
EGF 104–1000 0.994 MIP-1 90–1000 0.991
Endostatin 16–4000 0.999 MIP-1 4–1000 0.971
Eotaxin 104–1000 0.994 MIP-3 90–1000 0.992
Epo-R 10 000–20 000 0.999 MIP-3 83–1000 0.999
E-selectin 6–6000 0.987 MMP-3 2–2000 0.952
Fas ligand 63–2000 0.986 MMP-9 8–2000 0.997
Fcg RIIB/C 542–3000 0.985 MMP-13 1480–10 000 0.982
FGF basic 4–1000 0.974 OSM 500–2000 0.998
FGF-4 375–1000 0.999 P-cadherin 1667–4000 0.987
FGF-6 260–5000 0.971 PDGF-AB 73–1000 0.995
Fractalkine 5000–20000 0.982 PDGF-BB 183–2000 0.992
G-CSF 125–2000 0.983 Pro-cathepsin S 167–2000 0.992
GM-CSF 250–1000 0.998 P-selectin 8–8000 0.999
GRO 375–2000 0.989 RANTES 16–1000 0.997
HGF 375–8000 0.985 Resistin 8–2000 0.996
HSP27 (IC) 31–2000 0.998 sICAM-1 4–1000 0.976
HSP70 (IC) 1667–10 000 0.997 sTNF RI 233–1000 0.995
ICAM-3 500–2000 0.997 Survivin (IC) 667–4000 0.992
IFN 42–1000 0.997 TARC 96–500 0.995
IGFBP-2 4–4000 0.987 TGF- 47–1000 0.997
IGFBP-3 8–8000 0.976 TGF-1 500–4000 0.997
IL-1 RI 917–8000 0.997 TGF-2 1250–4000 0.997
IL-1 sRII 500–2000 0.960 TGF-3 500–2000 0.990
IL-1 208–1000 0.998 TIMP-1 500–2000 0.960
IL-1 42–1000 0.998 TIMP-2 8–2000 0.974
IL-2 94–1000 0.982 TIMP-4 750–2000 0.988
IL-3 333–1000 0.987 TNF 333–1000 0.997
IL-4 333–2000 0.991 uPAR 8–2000 0.975
IL-5 39–1500 0.996 VCAM-1 4–1000 0.976
IL-6 52–1000 0.982 VEGF 83–2000 0.984
IL-6 sR 8–1000 0.997 VEGF-D 375–2000 0.992
IL-8 73–2000 0.993 VEGF R2(IC) 8–2000 0.983
IL-10 4–4000 0.962 PAI-I 39–160 000 0.999
Fetuin-A/AHSG 195–800 000 0.997 IL-18 1–4000 0.999
IL-2 sR 6–24 000 0.994 KIM-1 4–16 000 0.999
IL-2 R 6–24 000 0.995 DAF 195–800 000 0.995
CLUSTERIN 156–640 000 0.998 Lactoferrin 4–14 000 0.999
Osteopontin 49–200 000 0.998 Annexin V 98–400 000 0.996
NGAL 10–40 000 0.995 Cystatin C 98–400 000 0.999
TNF RII 2–6400 0.998 Lymphotoxin  R 1–4000 0.997
Fibronectin 4–80 000 0.976 Lymphotoxin // 195–800 000 0.996
Human antibody chip range of detection (pg/mL) and correlation of the standard curves.
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